Greenwich LifeSciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GLSI research report →
Range $50 – $50
Price Chart
About the company
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies.
- CEO
- Snehal S. Patel
- IPO
- 2020
- Employees
- 13
- HQ
- Stafford, TX, US
Get TickerSpark's AI analysis on GLSI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $231.77M
- P/E
- -10.25
- Fwd P/E
- 3.97
- PEG
- 0.78
- P/S
- 0.00
- P/B
- 74.07
- EV/EBITDA
- -10.28
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -793.76%
- ROIC
- -701.55%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,779+50.7%
- Op Income
- $-19,447,918
- Net Income
- $-19,358,218-11.2%
- EPS
- $-1.43-18.2%
- OCF Growth
- -36.4%
- FCF Growth
- -36.4%
- 52W High
- $34.10
- 52W Low
- $7.78
- 50D MA
- $16.28
- 200D MA
- $21.93
- Beta
- 1.46
- RSI (14)
- 42
- Avg Volume
- 139.47K
No earnings-call transcripts are available for GLSI yet.
- Free Float
- 50.3%
- Shares Outstanding
- 14.68M
- Float Shares
- 7.38M
of shares held by institutions
63 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 485.85K | ▲ 51.99K |
| Vanguard Group Inc | 296.62K | ▲ 14.44K |
| Vanguard Capital Management LLC | 278.19K | ▼ 20.08K |
| Geode Capital Management, LLC | 168.18K | ▲ 12.71K |
| State Street Corp | 143.09K | ▲ 9.21K |
| Vanguard Portfolio Management LLC | 80.86K | ▲ 21.95K |
| Northern Trust Corp | 80.23K | ▲ 5.10K |
| Bank Of New York Mellon Corp | 47.90K | ▲ 1.38K |
| Vanguard Fiduciary Trust Co | 45.97K | ▲ 1.06K |
| Morgan Stanley | 43.45K | ▲ 13.62K |
| Goldman Sachs Group Inc | 39.33K | ▼ 192 |
| Russell Investments Group, Ltd. | 34.35K | ▼ 5.34K |
Held by 86 ETFs
Biggest fund positions in GLSI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 29, 26 | Patel Snehal | buy | 700 |
| Jul 28, 26 | Patel Snehal | buy | 1,500 |
| Jul 27, 26 | Patel Snehal | buy | 1,500 |
| Jul 24, 26 | Patel Snehal | buy | 1,100 |
| Jul 23, 26 | Patel Snehal | buy | 2,500 |
| Jan 13, 26 | Patel Snehal | buy | 1,800 |
| Jan 12, 26 | Patel Snehal | buy | 2,900 |
| Dec 31, 25 | Patel Snehal | buy | 4,300 |
| Dec 30, 25 | Patel Snehal | buy | 2,900 |
| Dec 18, 25 | Patel Snehal | buy | 4,100 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GLSI coverage
Recent articles, reports, and earnings notes.
No research on GLSI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GLSI report →Greenwich LifeSciences (NASDAQ:GLSI) Stock Falls 2.1% – Time to Sell?
defenseworld.net · Oct 4
20 stocks likely to lose money even if the bull market continues
marketwatch.com · Aug 27
Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
globenewswire.com · Aug 10
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
globenewswire.com · Jul 22
Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01
globenewswire.com · Jul 20
Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01
globenewswire.com · Jul 16
Greenwich LifeSciences The Overlooked Need
seekingalpha.com · Jul 16
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01
globenewswire.com · Jul 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.